Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.46 |
| ▸ | BCHE | P06276 | 7/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480408 | 1.00 | ACHE (0.46) | ACHEBCHEROCK2NAMPTHDAC1 | |
| SCHEMBL480409 | 1.00 | ACHE (0.46) | ACHEBCHEROCK2NAMPTHDAC1 | |
| Trifluoroacetic Acid SCHEMBL2573135 | 0.95 | ACHE (0.41) | ACHEBCHEROCK2NAMPTHDAC1 | |
| Trifluoroacetic Acid SCHEMBL2573132 | 0.95 | ACHE (0.41) | ACHEBCHEROCK2NAMPTHDAC1 | |
| SCHEMBL3141916 | 0.94 | HDAC1 (0.45) | ACHEBCHEROCK2HDAC1BACE1 | |
| SCHEMBL3141912 | 0.94 | HDAC1 (0.45) | ACHEBCHEROCK2HDAC1BACE1 | |
| SCHEMBL2572606 | 0.92 | MEN1 (0.39) | ACHEBCHEROCK2BACE1 | |
| SCHEMBL2572610 | 0.92 | MEN1 (0.39) | ACHEBCHEROCK2BACE1 | |
| SCHEMBL2121554 | 0.91 | ROCK2 (0.38) | ACHEBCHEROCK2BACE1 | |
| SCHEMBL480568 | 0.91 | LSS (0.40) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | ACHE 2390/4885BCHE 3302/4885ROCK2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.